Research & Development



  林徵羽晚上沒有直播,陸昔年怕影響他訓練,所以一直忍住沒打電話。和王淼淼雙排了晚上,大概是跟林徵羽一起打得久了,有些東西漸漸潛移默化,大局觀強了不少,順利的吃了好幾次雞。   陸昔年起床的時候小糯米還睡得很熟。彩票投注软件app下载   雲瑯的嘴被虎外婆粗暴的捏開,一大團帶著說不上來味道的白色油脂塞進了嘴里。宝马彩票送38   像是察覺到有人在看他似的,林徵羽回過頭來,陸昔年反射性的把門關上,然後迅速撲到床上。拖鞋被他踢到一邊也顧不得了,他慌慌忙忙的把被子扯過來蓋在頭頂。   “好好好,我出去。”林徵羽知道他在別扭什麼,依言退了出去。昨天清理的時候陸昔年的那處有點紅腫,雖然上了藥但不知道有沒有效,他擔心了一晚上,直到反復確認陸昔年沒發燒才松了口氣。彩票77下载app送27元   林徵羽不說他還不覺得,一說陸昔年便感覺胃里空蕩蕩的,光是腦補的畫面就讓他食指大動。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo